Parallax Volatility Advisers, L.P. Ionis Pharmaceuticals Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$40.06 - $51.86 $1.99 Million - $2.58 Million	-49,700 Reduced 80.68%	11,900 $476,000
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $2.25 Million - $2.94 Million	61,600 New	61,600 $2.94 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $190,008 - $253,031	5,200 New	5,200 $230,000
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $1.31 Million - $1.79 Million	37,800 Added 756.0%	42,800 $1.71 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $254,016 - $389,616	4,800 Added 2400.0%	5,000 $406,000
Q4 2018 Feb 14, 2019	SELL	$43.37 - $59.54 $858,726 - $1.18 Million	-19,800 Reduced 99.0%	200 $11,000
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $810,600 - $1.01 Million	20,000 New	20,000 $833,000
Q4 2017 Feb 14, 2018	SELL	$50.3 - $64.39 $905,400 - $1.16 Million	-18,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $820,080 - $1.07 Million	18,000	18,000 $913,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.19B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.